Most recent product introduction is a new device we called AFX, it stands for anatomical fixation which is that platform sitting on the bifurcation. The features of this new device is it got a relatively low profile system, but most importantly is this new graft materially called Strata. And I will talk to you little bit about this as we go through the presentation.

We developed a new graft material for one of our other new product called Ventana. And this graft material is very, very strong and highly conformable and crates very good sealing characteristics for the device.

From the sales perspective, at the end of the third quarter we had 72 reps and clinical specialist. We plan next year to be at 66 reps and 11 clinical specialist, they are total of 77 feet on the street in the United States. As you can see over 400 years of EVAR experience, it's important to know that the reps and the clinical specialist work every case. So, we have somebody there to support the doctor for all their procedures and we just this last quarter transition to direct sales operation in Europe, previously we sold in most of Western Europe through our distribution partner and are now in the process of building our own team. We plan to finish this year with about 12 full time folks on the ground in Europe and grow that up by the end of next year to about 30, still covered in Asia and Latin America through dealers.

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

Endologix Poised for a Potentially Volatile Breakout

5 Stocks Trending Close to Major Breakouts

5 Stocks Set for Explosive Breakouts

These 5 Stocks Under $10 Could Make You a Lot of Money

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains